The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily...
- Mechanism
- Curator reviewed
Cediranib inhibits vacular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK). By forming a blockade at the VEGF receptors, Cediranib limits the growth of new blood vessels, which are essential to supporting tumor growth. Thus, lacking sufficient blood supply, tumor cells become starved for nutrients, slowing or halting growth and potentially improving the efficacy of other treatments. Preclinical evidence indicated that the drug had a high affinity at these sites, and was well tolerated and efficacious in animal studies.
- Primary indication
- For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.Curator reviewed
- Formula / weight
- C25H27FN4O3 · 450.5053 g/mol (avg)
- Code names
- AZ-D2171
Resolves to
XXJWYDDUDKYVKI-UHFFFAOYSA-NSMILESCOC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Cediranib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account